[REVISION HISTORY]

GLP-1 drugs: clinical trends, safety, and market shifts

Updated 39 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-10 04:23 UTC → 2026-09-10 23:16 UTC · added ~~removed~~

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. ~~While research~~ Research suggests secondary ~~benefits—including~~ benefits, including a 21% lower risk of fragility fractures in older adults, potential liver protection, and improved obstructive sleep apnea ~~remission—new therapeutic possibilities are emerging. Research presented at~~ remission. New findings from the ~~European Respiratory Society Congress suggests~~ UK suggest semaglutide may ~~be associated with up to a 40% reduction in~~ reduce asthma ~~attacks. Furthermore,~~ attacks, while the SELECT study ~~involving over 17,000 participants found~~ confirmed that weekly semaglutide use reduced ~~the risk of~~ major cardiovascular ~~events, such as heart attack or stroke,~~ event risks by approximately 20 percent in specific overweight or obese ~~individuals with cardiovascular disease but without diabetes.~~ populations. However, new safety and usage concerns ~~have surfaced.~~ persist. A ~~study identified a~~ genetic link ~~between GLP-1 receptor agonists and an increased risk of~~ to male-pattern ~~baldness. Additionally, the term ‘Ozempic teeth’~~ baldness has ~~emerged on social media to describe dental issues like~~ been identified, and ‘Ozempic teeth’—dental enamel erosion caused by ~~side effects such as~~ nausea and ~~vomiting. Other systemic risks include muscle and bone loss, hair loss, and skin sagging.~~ vomiting—has emerged on social media. To ~~address~~ mitigate gastrointestinal side effects, researchers are ~~exploring whether~~ investigating the use of probiotics like Bacillus ~~clausii could mitigate symptoms. Clinical applications are expanding into younger populations, with~~ clausii. Additionally, the rise in adolescent prescriptions, including approximately 33,000 ~~prescriptions~~ for Wegovy and Zepbound ~~issued to individuals under 18~~ in the U.S. last ~~year. This rise~~ year, has ~~raised~~ fueled concerns regarding body image ~~distortions among adolescents.~~ distortions. Economic and regulatory shifts are also emerging. The medications are reportedly driving a 20% decrease in restaurant consumption and alcohol sales as they act on the brain’s reward centers. In South Korea, experts are calling for a data-driven management system to prevent misuse for cosmetic purposes while ensuring access for high-need patients. To support long-term ~~success and mitigate weight regain, experts suggest~~ success, researchers advocate for a ‘digital behavioral infrastructure’—using companion apps to leverage the ‘habit window’ created by reduced ‘food noise’—to help patients establish sustainable lifestyle routines.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.